| 2023-03-21 | -61.1% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-06-26 | -55.9% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-06-26 | -55.9% | analyst | Seeking Alpha | Altimmune: Deciphering The MASH Crash (Rating Upgrade) (NASDAQ:ALT) - Seeking Alpha |
| 2025-06-26 | -55.9% | news | Seeking Alpha | Altimmune stock plunges on MASH drug trial data (ALT:NASDAQ) - Seeking Alpha |
| 2022-12-20 | +41.5% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2021-06-29 | -39.7% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-08-11 | +33.3% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2024-11-12 | +29.8% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2024-11-12 | +29.8% | legal | SEC EDGAR | ALT 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-05-12 | +28.7% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2022-09-14 | -28.6% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-19 | -19.3% | news | Seeking Alpha | Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript |
| 2025-12-19 | -19.3% | news | Seeking Alpha | Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH |
| 2025-12-19 | -19.3% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-19 | -19.3% | news | Investing.com | Altimmune stock tumbles after MASH drug trial data - Investing.com |
| 2025-12-19 | -19.3% | news | StocksToTrade | ALT Stock Surge: Should You Act? - StocksToTrade |
| 2025-12-19 | -19.3% | news | Stock Titan | Trial drug for fatty liver disease improves key markers at 48 weeks - Stock Titan |
| 2025-12-19 | -19.3% | news | Stocktwits | Why Is Altimmune Stock Up Over 10% Before The Bell? - Stocktwits |
| 2026-04-23 | -18.3% | news | Zacks | Altimmune Catalysts: 2026 Data Readouts and Financing Risks |
| 2026-04-23 | -18.3% | news | Zacks | ALT Stock: What Pemvidutide Means for MASH, AUD and ALD |
| 2026-04-23 | -18.3% | news | Zacks | Is Altimmune a Buy Before Phase III MASH Starts in 2026? |
| 2026-04-23 | -18.3% | news | MT Newswires | Altimmune Prices $225 Million Public Offering; Shares Fall Pre-Bell |
| 2026-04-23 | -18.3% | legal | GlobeNewswire | Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities |
| 2026-04-23 | -18.3% | legal | Seeking Alpha | Altimmune prices $225M public offering of securities |
| 2026-04-23 | -18.3% | news | TradingView | ALT Stock: What Pemvidutide Means for MASH, AUD and ALD - TradingView |
| 2026-04-23 | -18.3% | news | Benzinga | Why Is Altimmune Stock Falling Today? - Benzinga |
| 2026-04-23 | -18.3% | news | StocksToTrade | ALT Stock Slides As Equity Offering Funds Phase 3 MASH Push - StocksToTrade |
| 2026-04-23 | -18.3% | news | MSN | Dilution fears return: Why ALT stock is getting hit again - MSN |
| 2026-04-23 | -18.3% | news | TradingView | Is Altimmune a Buy Before Phase III MASH Starts in 2026? - TradingView |
| 2026-04-23 | -18.3% | news | Stock Titan | $225M Altimmune raise is slated to fund a Phase 3 MASH trial - Stock Titan |
| 2026-04-23 | -18.3% | news | TradingView | Altimmune Catalysts: 2026 Data Readouts and Financing Risks - TradingView |
| 2026-04-23 | -18.3% | news | timothysykes.com | Altimmune Stock Pressured As Equity Offering Fuels Phase 3 MASH Push - timothysykes.com |
| 2026-04-23 | -18.3% | earnings | UBND thành phố Hải Phòng | Resistance Test Overview | Altimmune Inc. reports 10.2% EPS miss wider loss - Competitive Risk - UBND thành phố Hải Phòng |
| 2026-01-28 | -17.3% | news | Seeking Alpha | Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet |
| 2026-01-28 | -17.3% | news | Seeking Alpha | Altimmune prices $75M direct offering |
| 2026-01-28 | -17.3% | legal | SEC EDGAR | ALT 8-K: 1.01 and (SEC Filing) |
| 2026-01-28 | -17.3% | news | Seeking Alpha | Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha |
| 2026-01-28 | -17.3% | news | Investing.com South Africa | Altimmune stock falls after announcing $75 million direct offering By Investing.com - Investing.com South Africa |
| 2026-01-28 | -17.3% | M&A | Stocktwits | ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits |
| 2026-01-28 | -17.3% | news | StocksToTrade | Altimmune Stock Volatility Spurs Investor Attention - StocksToTrade |
| 2026-01-28 | -17.3% | expansion | TradingView | Altimmune Signs Multiple Material Agreements - TradingView |
| 2026-01-28 | -17.3% | news | Benzinga | Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga |
| 2024-03-27 | +16.9% | legal | SEC EDGAR | ALT 8-K: 2.02, 8.01 (SEC Filing) |
| 2026-03-04 | -15.9% | earnings | Seeking Alpha | Altimmune Q4 2025 Earnings Preview |
| 2026-04-22 | -15.9% | legal | GlobeNewswire | Altimmune Announces Proposed Underwritten Public Offering of Securities |
| 2026-04-22 | -15.9% | expansion | Seeking Alpha | Altimmune launches proposed public offering to fund late-stage trial |
| 2026-04-22 | -15.9% | analyst | Seeking Alpha | Altimmune: Why I'm Downgrading To Hold Despite MASH Promise |
| 2026-04-22 | -15.9% | news | Stock Titan | Altimmune seeks Phase 3 liver trial funds in stock sale - Stock Titan |
| 2026-04-22 | -15.9% | expansion | Quiver Quantitative | Altimmune, Inc. Launches Public Offering of Common Stock and Warrants to Fund Phase 3 Trial for Pemvidutide - Quiver Quantitative |
| 2026-04-22 | -15.9% | analyst | Seeking Alpha | Altimmune: Why I'm Downgrading To Hold Despite MASH Promise (NASDAQ:ALT) - Seeking Alpha |
| 2026-04-22 | -15.9% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Resistance Test Overview | Altimmune Inc. reports 10.2% EPS miss wider loss - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-03-05 | -15.2% | news | Seeking Alpha | Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances |
| 2026-03-05 | -15.2% | earnings | Seeking Alpha | Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript |
| 2026-03-05 | -15.2% | news | Seeking Alpha | Altimmune to start late-stage trial for MASH candidate this year |
| 2026-03-05 | -15.2% | earnings | Seeking Alpha | Altimmune GAAP EPS of -$0.27 misses by $0.03, revenue of $0.03M beats by $0.03M |
| 2026-03-05 | -15.2% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | -15.2% | earnings | ChartMill | Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones - ChartMill |
| 2026-03-05 | -15.2% | earnings | Investing.com | Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com |
| 2026-03-05 | -15.2% | news | Seeking Alpha | Altimmune to start MASH late-stage trial in 2026 (ALT:NASDAQ) - Seeking Alpha |
| 2026-03-05 | -15.2% | earnings | Investing.com | Altimmune stock edges down on fourth quarter earnings miss - Investing.com |
| 2026-03-05 | -15.2% | legal | Stock Titan | FDA grants Breakthrough Therapy designation to liver disease drug pemvidutide - Stock Titan |
| 2021-09-28 | -14.1% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-06-26 | -14.1% | legal | SEC EDGAR | ALT 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-11-30 | +13.1% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2021-06-16 | +12.8% | legal | SEC EDGAR | ALT 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-02-27 | +12.0% | legal | SEC EDGAR | ALT 8-K: 2.02, 5.02 (SEC Filing) |
| 2025-11-21 | +11.6% | news | simplywall.st | While institutions invested in Altimmune, Inc. (NASDAQ:ALT) benefited from last week's 10% gain, individual investors stood to gain the most - simplywall.st |
| 2026-01-05 | +11.6% | legal | Seeking Alpha | Altimmune gains on FDA breakthrough designation for MASH therapy |
| 2026-01-05 | +11.6% | legal | Seeking Alpha | Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha |
| 2026-01-05 | +11.6% | news | StocksToTrade | Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade |
| 2026-01-05 | +11.6% | legal | Stock Titan | FDA flags new liver disease drug for faster review after promising early data - Stock Titan |
| 2026-03-06 | +11.1% | news | Seeking Alpha | Altimmune Reports FY 2025 Financials: Why Is Big Pharma Staying Away? |
| 2026-03-06 | +11.1% | news | DirectorsTalk Interviews | Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 404% Upside In Biotech - DirectorsTalk Interviews |
| 2026-03-06 | +11.1% | news | Seeking Alpha | Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha |
| 2026-03-06 | +11.1% | news | Meyka | William Blair Maintains Market Perform on ALT (Altimmune, Inc.) March 2026 - Meyka |
| 2025-11-06 | +10.6% | legal | Seeking Alpha | Altimmune outlines flexible Phase III design and regulatory milestones while strengthening leadership |
| 2025-11-06 | +10.6% | earnings | Seeking Alpha | Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript |
| 2025-11-06 | +10.6% | earnings | Seeking Alpha | Altimmune GAAP EPS of -$0.21 beats by $0.05, revenue of $0.05M beats by $0.05M |
| 2025-11-06 | +10.6% | legal | SEC EDGAR | ALT 8-K: 1.01, 1.02 (SEC Filing) |
| 2025-11-06 | +10.6% | legal | SEC EDGAR | ALT 8-K: 1.01, 2.02, 2.03 (SEC Filing) |
| 2026-01-27 | -9.9% | news | Yahoo Finance | Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - Yahoo Finance |
| 2026-01-27 | -9.9% | news | Stock Titan | Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan |
| 2026-01-29 | +9.9% | news | Yahoo Finance | Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Yahoo Finance |
| 2026-01-29 | +9.9% | news | Stock Titan | Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial - Stock Titan |
| 2024-08-08 | +9.4% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-08-12 | +9.2% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-12-01 | -9.2% | executive | Seeking Alpha | Altimmune announces CEO transition |
| 2025-12-01 | -9.2% | legal | SEC EDGAR | ALT 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-12-01 | -9.2% | executive | Stock Titan | Altimmune (Nasdaq: ALT) details CEO handover and late-stage pemvidutide path in MASH - Stock Titan |
| 2025-12-01 | -9.2% | executive | Investing.com | Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com |
| 2026-03-09 | +8.3% | executive | Investing.com | Altimmune CEO Durso buys $70,790 in shares - Investing.com |
| 2026-03-09 | +8.3% | executive | Investing.com | Altimmune CFO Weaver buys $17,700 in shares - Investing.com |
| 2026-03-27 | -8.0% | earnings | Investing.com | Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com |
| 2026-04-01 | +7.6% | executive | Stock Titan | Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - Stock Titan |
| 2026-04-01 | +7.6% | executive | Stock Titan | Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - Stock Titan |
| 2025-08-27 | +7.3% | analyst | Seeking Alpha | Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha |
| 2025-11-07 | +6.5% | analyst | GuruFocus | Altimmune (ALT) Analyst Rating Update: Price Target Lowered by C - GuruFocus |
| 2021-05-17 | +6.3% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2026-02-03 | -6.2% | news | Seeking Alpha | Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 |
| 2026-02-03 | -6.2% | legal | SEC EDGAR | ALT 8-K: 8.01 (SEC Filing) |
| 2026-02-03 | -6.2% | news | Seeking Alpha | Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha |
| 2021-08-10 | +6.2% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2021-12-13 | -6.2% | legal | SEC EDGAR | ALT 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-03-13 | +6.0% | legal | SEC EDGAR | ALT 8-K: 8.01 (SEC Filing) |
| 2025-05-13 | -5.9% | legal | SEC EDGAR | ALT 8-K: 1.01, 2.02, 2.03, 7.01 (SEC Filing) |
| 2026-03-12 | -5.8% | analyst | Seeking Alpha | Altimmune: The High Cost Of Going Solo (Rating Downgrade) |
| 2026-03-12 | -5.8% | news | Seeking Alpha | Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2026-03-12 | -5.8% | analyst | Seeking Alpha | Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha |
| 2025-12-21 | +5.5% | executive | timothysykes.com | Altimmune Stock Plummets After Disappointing Trial Results - timothysykes.com |
| 2025-12-20 | +5.5% | news | Seeking Alpha | Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH - Slideshow |
| 2025-07-24 | -5.4% | analyst | Seeking Alpha | Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade) (ALT) - Seeking Alpha |
| 2026-04-10 | -5.3% | news | Cổng thông tin điện tử tỉnh Tây Ninh | What is the sentiment around Altimmune (ALT) Stock | Price at $3.23, Down 4.29% - Community Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2025-11-20 | +5.3% | news | Seeking Alpha | Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript |
| 2026-03-26 | -5.3% | news | Yahoo Finance | Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - Yahoo Finance |
| 2026-03-26 | -5.3% | news | Stock Titan | Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan |
| 2024-12-11 | -4.9% | legal | SEC EDGAR | ALT 8-K: 8.01 (SEC Filing) |
| 2025-12-23 | -4.7% | news | Seeking Alpha | Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha |
| 2025-12-23 | -4.7% | earnings | MarketBeat | John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat |
| 2026-01-23 | +4.7% | earnings | MarketBeat | Stock Traders Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT) - MarketBeat |
| 2026-01-23 | +4.7% | legal | StocksToTrade | Altimmune Stock Surges After FDA Breakthrough for MASH Therapy - StocksToTrade |
| 2026-02-26 | -4.4% | news | Stock Titan | Liver disease drug developer Altimmune to detail 2025 finances on March 5 - Stock Titan |
| 2026-03-17 | -4.4% | analyst | Investing.com | H.C. Wainwright raises Altimmune stock price target on MASH focus - Investing.com |
| 2026-04-09 | -4.4% | news | Seeking Alpha | Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap |
| 2026-04-09 | -4.4% | news | Seeking Alpha | Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap (NASDAQ:ALT) - Seeking Alpha |
| 2026-04-09 | -4.4% | news | UBND thành phố Hải Phòng | What are the biggest risks for Altimmune (ALT) Stock | Price at $3.35, Down 0.50% - Wall Street Picks - UBND thành phố Hải Phòng |
| 2026-04-09 | -4.4% | news | Cổng thông tin điện tử Tỉnh Sơn La | What are the biggest risks for Altimmune (ALT) Stock | Price at $3.35, Down 0.50% - Resistance Breakout - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-12-28 | -4.3% | news | simplywall.st | Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st |
| 2025-11-14 | +4.1% | news | Seeking Alpha | Altimmune: Probing Pemvi's MASH Data |
| 2025-11-14 | +4.1% | news | Seeking Alpha | Altimmune Stock: Probing Pemvi's MASH Data (NASDAQ:ALT) - Seeking Alpha |
| 2025-12-24 | -3.8% | news | Seeking Alpha | Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen |
| 2022-11-10 | +3.8% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-09-10 | -3.5% | news | Seeking Alpha | Altimmune: Pemvidutide Shows Promise In MASH, But Lacks Competitive Edge - Seeking Alpha |
| 2024-08-15 | +3.1% | legal | SEC EDGAR | ALT 8-K: 5.02 and (SEC Filing) |
| 2025-08-15 | -3.0% | legal | Stock Titan | ALT SEC Filings - Altimmune 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2023-02-28 | +2.6% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2023-05-11 | +2.5% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2023-03-27 | +2.4% | legal | SEC EDGAR | ALT 8-K: 5.02 and (SEC Filing) |
| 2025-02-25 | -2.3% | legal | SEC EDGAR | ALT 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-03-15 | -2.3% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-12-04 | +2.3% | news | Seeking Alpha | Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company |
| 2025-12-04 | +2.3% | news | Seeking Alpha | Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha |
| 2026-02-17 | -2.2% | analyst | Yahoo Finance | Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Yahoo Finance |
| 2026-01-06 | +2.2% | legal | Yahoo Finance | ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Yahoo Finance |
| 2025-12-11 | -2.1% | analyst | Yahoo Finance | Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Yahoo Finance |
| 2023-08-10 | +2.1% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-10-30 | +2.0% | M&A | Seeking Alpha | Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha |
| 2025-10-30 | +2.0% | news | Stock Titan | Altimmune (Nasdaq: ALT) schedules Nov 6 results call at 8:30 a.m. ET with business update - Stock Titan |
| 2026-02-02 | -2.0% | analyst | Yahoo Finance | Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Yahoo Finance |
| 2026-04-19 | +1.9% | news | Simply Wall St. | Independent Non-Executive Director of Altitude Group Picks Up 100% More Stock |
| 2025-10-03 | +1.7% | legal | SEC EDGAR | ALT 8-K: 5.02 (SEC Filing) |
| 2025-10-03 | +1.7% | news | DirectorsTalk Interviews | Altimmune, Inc. (ALT) Stock Analysis: A Biotech Gem With 337% Potential Upside - DirectorsTalk Interviews |
| 2025-09-19 | +1.6% | news | DirectorsTalk Interviews | Altimmune, Inc. (ALT) Stock Analysis: Uncovering A 344% Potential Upside In Biotech - DirectorsTalk Interviews |
| 2026-04-16 | +1.5% | news | MarketBeat | Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M |
| 2026-04-16 | +1.5% | news | Stock Titan | Altimmune (NASDAQ: ALT) shareholders approve doubling share authorization - Stock Titan |
| 2025-12-22 | +1.5% | news | Seeking Alpha | Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates |
| 2025-12-22 | +1.5% | news | Seeking Alpha | Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha |
| 2026-03-18 | -1.5% | news | Seeking Alpha | Altimmune a new buy at Truist on pemvidutide promise |
| 2025-10-08 | +1.5% | news | Yahoo Finance | Pleasing Signs As A Number Of Insiders Buy Altimmune Stock - Yahoo Finance |
| 2025-08-13 | +1.3% | news | Yahoo Finance | Individual investors account for 51% of Altimmune, Inc.'s (NASDAQ:ALT) ownership, while institutions account for 48% - Yahoo Finance |
| 2025-08-13 | +1.3% | earnings | Yahoo Finance | Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... - Yahoo Finance |
| 2025-10-10 | +1.2% | news | DirectorsTalk Interviews | Altimmune, Inc. (ALT) Stock Analysis: Exploring A 311% Potential Upside In Biotech - DirectorsTalk Interviews |
| 2025-11-11 | -1.0% | news | Seeking Alpha | Altimmune releases additional phase 2 pemvidutide data for MASH |
| 2026-04-05 | -0.8% | analyst | timothysykes.com | Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com |
| 2023-11-07 | +0.8% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | +0.7% | news | Stock Titan | Altimmune (ALT) director makes open-market share purchase - Stock Titan |
| 2026-04-06 | +0.7% | news | Investing.com | Altimmune director Gill buys $31k in company stock - Investing.com |
| 2026-04-06 | +0.7% | news | Cổng thông tin điện tử Tỉnh Sơn La | Will Altimmune (ALT) Stock Go Higher | Price at $3.42, Up 2.40% - Short Term Trading - Cổng thông tin điện tử Tỉnh Sơn La |
| 2021-11-09 | +0.7% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | -0.7% | news | Cổng thông tin điện tử Tỉnh Sơn La | Does Altimmune (ALT) Stock pay reliable income | Price at $3.21, Down 0.93% - Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-05-21 | +0.3% | analyst | Yahoo Finance | Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - Yahoo Finance |
| 2025-11-25 | -0.3% | analyst | Yahoo Finance | Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - Yahoo Finance |
| 2024-05-09 | +0.1% | legal | SEC EDGAR | ALT 8-K: 2.02 and (SEC Filing) |
| 2025-12-12 | +0.1% | news | TechStock² | Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts - TechStock² |
| 2026-03-25 | +0.0% | news | Yahoo Finance | H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Yahoo Finance |
| 2026-04-26 | — | news | Insider Monkey | Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock |
| 2026-04-26 | — | news | Yahoo Finance | Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Yahoo Finance |
| 2026-04-26 | — | news | Insider Monkey | Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey |
| 2026-04-24 | — | analyst | MT Newswires | Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1 |
| 2026-04-24 | — | legal | SEC EDGAR | ALT 8-K: 1.01 and (SEC Filing) |
| 2026-04-24 | — | analyst | ChartMill | ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill |
| 2026-04-24 | — | news | Stock Titan | Altimmune (NASDAQ: ALT) prices $3.00 stock and warrant offering - Stock Titan |
| 2026-04-24 | — | news | Stock Titan | Altimmune (NASDAQ: ALT) prices 64.25M shares with warrants to fund Phase 3 - Stock Titan |
| 2026-04-24 | — | news | TradingView | Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays - TradingView |